San Diego, CA, United States of America

Monica Leung

USPTO Granted Patents = 2 

Average Co-Inventor Count = 7.8

ph-index = 2

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2019-2020

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Monica Leung in Psoriasis Treatment

Introduction

Monica Leung is an accomplished inventor based in San Diego, CA. She has made significant contributions to the field of immunology, particularly in the treatment of autoimmune diseases. With a total of 2 patents, her work focuses on innovative methods that utilize PD-1 binding antibodies.

Latest Patents

Monica's latest patents include groundbreaking methods for treating psoriasis using PD-1 binding antibodies. These methods provide new approaches for managing, treating, or preventing immune disorders, such as autoimmune diseases, by using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate its expression and activity. Additionally, she has developed compositions and methods involving antibodies that specifically bind to PD-1, further enhancing the understanding and treatment of immune-related conditions.

Career Highlights

Monica Leung is currently associated with Celgene Corporation, where she continues to advance her research and innovations. Her work has garnered attention for its potential to transform treatment protocols for patients suffering from autoimmune diseases.

Collaborations

Monica collaborates with notable colleagues, including Henry Chan and Roli Khattri, who contribute to her research endeavors and help drive her innovative projects forward.

Conclusion

Monica Leung's contributions to the field of immunology, particularly through her patents related to PD-1 binding antibodies, highlight her role as a leading inventor in the treatment of autoimmune diseases. Her work promises to pave the way for new therapeutic strategies that can significantly improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…